CYP2D6*3, *4, *6 GENOTYPES AND ENDOMETRIAL THICKNESS IN PATIENTS WITH BREAST CANCER DURING TAMOXIFEN THERAPY

被引:0
作者
Goryainova, A. Yu [1 ,2 ,6 ]
Usman, N. Yu [3 ]
Rubanovich, A., V [4 ]
Borinskaya, S. A. [4 ]
Meshcheryakov, A. A. [5 ]
机构
[1] Clin Oncol Dispensary 1, Krasnodar, Russia
[2] Kuban State Med Univ, Krasnodar, Russia
[3] Kulakov Natl Med Res Ctr Obstet Gynecol & Perinato, Moscow, Russia
[4] Russian Acad Sci, Vavilov Inst Gen Genet, Moscow, Russia
[5] Fed Med Biol Agcy, Lopukhin Fed Res & Clin Ctr Phys Chem Med, Moscow, Russia
[6] Dimitrov 146, Krasnodar 350040, Russia
来源
BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY | 2023年 / 05期
关键词
breast cancer; tamoxifen; endometrial thickness; endocrine therapy; BONE-MINERAL DENSITY; CYP2D6; PROGNOSIS; POLYMORPHISMS; GUIDELINE;
D O I
10.24075/vrgmu.2023.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tamoxifen therapy results in endometrial thickening in some patients with hormone-sensitive breast cancer (HSBC). The data on the impact of polymorphic variants of the CYP2D6 gene encoding the CYP2D6 enzyme of the cytochrome P450 family on the efficacy and safety of treatment with tamoxifen are controversial. A prospective cohort study was aimed to explore the association of CYP2D6*3, *4, *6 polymorphisms with the risk of endometrial thickness during adjuvant tamoxifen therapy for HSBC. A total of 145 patients with resectable HSBC, who received 20 mg of oral tamoxifen per day, were enrolled. The CYP2D6*3, *4, *6 polymorphisms were identified by real-time PCR. Endometrial thickness was measured by ultrasonography after 3, 6 and 9 months of endocrine therapy. The study showed that endometrial hyportrophy was more often found in patients having no alternative alleles after 3 months of follow-up (40% against 23.2% in the group of "poor" metabolizers; p = 0.034). Meta-analysis of all follow-up periods has revealed that "normal" metabolizers show a significantly higher rate of endometrial thickness than "poor" metabolizers (OR = 1.88; 95% CI = 1.27-2.79; p = 0.002). A lack of significant differences in indicators of the state of endometrium between groups of patients with different CYD2D6 genotypes and menopausal status requires further investigation.
引用
收藏
页码:18 / 25
页数:8
相关论文
共 29 条
[1]  
[Anonymous], 2021, Rak molochnoy zhelezy. Klinicheskie rekomendatsii, P93
[2]   Guideline No. 392-Classification and Management of Endometrial Hyperplasia [J].
Auclair, Marie-Helene ;
Yong, Paul J. ;
Salvador, Shannon ;
Thurston, Jackie ;
Colgan, Terence J. ;
Sebastianelli, Alexandra .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2019, 41 (12) :1789-1800
[3]   Risk and prognosis of endometrial cancer after tamoxifen for breast cancer [J].
Bergman, L ;
Beelen, MLR ;
Gallee, MPW ;
Hollema, H ;
Benraadt, J ;
van Leeuwen, FE .
LANCET, 2000, 356 (9233) :881-887
[4]   CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].
Bradford, LD .
PHARMACOGENOMICS, 2002, 3 (02) :229-243
[5]  
Briest Susanne, 2009, Clin Adv Hematol Oncol, V7, P185
[6]   Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors [J].
Chlebowski, Rowan T. ;
Schottinger, Joanne E. ;
Shi, Jiaxiao ;
Chung, Joanie ;
Haque, Reina .
CANCER, 2015, 121 (13) :2147-2155
[7]   The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen [J].
Dieudonne, A. -S. ;
Lambrechts, D. ;
Smeets, D. ;
Belmans, A. ;
Wildiers, H. ;
Paridaens, R. ;
Hyonil, C. ;
Timmerman, D. ;
Christiaens, M. -R. ;
Vergote, I. ;
Neven, P. .
ANNALS OF ONCOLOGY, 2014, 25 (01) :90-95
[8]   Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort [J].
Dottino, Joseph A. ;
Zhang, Qian ;
Loose, David S. ;
Fellman, Bryan ;
Melendez, Brenda D. ;
Borthwick, Mikayla S. ;
McKenzie, Laurie J. ;
Yuan, Ying ;
Yang, Richard K. ;
Broaddus, Russell R. ;
Lu, Karen H. ;
Soliman, Pamela T. ;
Yates, Melinda S. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (03)
[9]   Tamoxifen and Endometrial Cancer: A Janus-Headed Drug [J].
Emons, Gunter ;
Mustea, Alexander ;
Tempfer, Clemens .
CANCERS, 2020, 12 (09) :1-11
[10]   Uterine serous carcinoma: key advances and novel treatment approaches [J].
Ferriss, J. Stuart ;
Erickson, Britt K. ;
Shih, Ie-Ming ;
Fader, Amanda N. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (08) :1165-1174